June 2, 2023

We describe improved responses in T-ALL patients during a Phase I dose study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) following the addition of tyrosine kinase inhibitors during manufacturing.

November 13, 2019

We describe a Phase I dose escalation study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) therapy for relapsed or refractory (r/r) T-cell leukemia and lymphoma.

March 5, 2019

In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity.


November 17, 2023

March Biosciences Awarded $13.4 Million by CPRIT to Advance Its CD5 CAR-T Therapy for T-cell Lymphoma in Phase 2 Trials

March Biosciences received a $13.4 million grant award from CPRIT to support continued clinical development of MB-105 CD5 CAR-T for T-cell lymphoma

November 9, 2023

Cancer Focus Fund invests $4.8M into Houston-based March Biosciences

The Cancer Focus Fund LP invested $4.8 million into a cell therapy company that has already tapped some of Houston’s growing life sciences resources.

November 9, 2023

March Biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma

Houston-Based Scientists, Entrepreneurs, Clinical Centers, Manufacturers and Investors Collaborate to Advance Promising New Approach for Patients with Few Treatment Options
All News Loaded